Apellis reports preliminary EMPAVELI FY2021 U.S. net product revenue of ~$15M

Apellis Pharmaceuticals, Inc.

2022-FY EPS reported -$8.84 revenue$66,563,000

Preliminary FY2021 U.S. net product revenue for EMPAVELI ~$15 million (unaudited).
Over 125 start forms submitted; >95% patient compliance; zero meningococcal infections.
More than 75% of new EMPAVELI starts are switches from competitor Ultomiris.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.